, Volume 14, Issue 2, pp 321–332

New Directions in Anti-Angiogenic Therapy for Glioblastoma


DOI: 10.1007/s13311-016-0510-y

Cite this article as:
Wang, N., Jain, R.K. & Batchelor, T.T. Neurotherapeutics (2017) 14: 321. doi:10.1007/s13311-016-0510-y


Anti-angiogenic therapy has become an important component in the treatment of many solid tumors given the importance of adequate blood supply for tumor growth and metastasis. Despite promising preclinical data and early clinical trials, anti-angiogenic agents have failed to show a survival benefit in randomized controlled trials of patients with glioblastoma. In particular, agents targeting vascular endothelial growth factor (VEGF) appear to prolong progression free survival, possibly improve quality of life, and decrease steroid usage, yet the trials to date have demonstrated no extension of overall survival. In order to improve duration of response and convey a survival benefit, additional research is still needed to explore alternative pro-angiogenic pathways, mechanisms of resistance, combination strategies, and biomarkers to predict therapeutic response.


Angiogenesis Glioblastoma Glioma Bevacizumab VEGF 

Supplementary material

13311_2016_510_MOESM1_ESM.pdf (932 kb)
ESM 1(PDF 932 kb)

Copyright information

© The American Society for Experimental NeuroTherapeutics, Inc. 2017

Authors and Affiliations

  • Nancy Wang
    • 1
  • Rakesh K. Jain
    • 2
  • Tracy T. Batchelor
    • 1
    • 2
    • 3
  1. 1.Stephen E. and Catherine Pappas Center for Neuro-OncologyMassachusetts General HospitalBostonUSA
  2. 2.Department of Radiation OncologyMassachusetts General HospitalBostonUSA
  3. 3.Department of Hematology/OncologyMassachusetts General HospitalBostonUSA

Personalised recommendations